PSYCHOSOCIAL PREDICTORS OF THE PLACEBO RESPONSE IN A RANDOMIZED CLINICAL TRIAL FOR MAJOR DEPRESSIVE DISORDER (MDD)

被引：0
|
作者：
Tartter, Margaret A. [1 ]
Leuchter, Andrew F. [1 ]
Hunter, Aimee F. [1 ]
Cook, Ian A. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
PSYCHOSOMATIC MEDICINE | 2014年 / 76卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：A121 / A121
页数：1
相关论文
共 50 条
  • [41] Cilostazol as an adjunctive treatment in major depressive disorder: a pilot randomized, double-blind, and placebo-controlled clinical trial
    Aida Khadivi
    Parnian Shobeiri
    Sara Momtazmaneh
    Farhaneh-Sadat Samsami
    Mohammadreza Shalbafan
    Elham Shirazi
    Shahin Akhondzadeh
    [J]. Psychopharmacology, 2022, 239 : 551 - 559
  • [42] AUGMENTATION OF FLUOXETINE WITH LOVASTATIN FOR TREATING MAJOR DEPRESSIVE DISORDER, A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED-CLINICAL TRIAL
    Ghanizadeh, Ahmad
    Hedayati, Arvin
    [J]. DEPRESSION AND ANXIETY, 2013, 30 (11) : 1084 - 1088
  • [43] Neuroimaging Genomics a Predictor of Major Depressive Disorder (MDD)
    Manav Jindal
    Aakash Chhetri
    Abhilash Ludhiadch
    Paramdeep Singh
    Sameer Peer
    Jawahar Singh
    Rahatdeep Singh Brar
    Anjana Munshi
    [J]. Molecular Neurobiology, 2024, 61 : 3427 - 3440
  • [44] Cilostazol as an adjunctive treatment in major depressive disorder: a pilot randomized, double-blind, and placebo-controlled clinical trial
    Khadivi, Aida
    Shobeiri, Parnian
    Momtazmaneh, Sara
    Samsami, Farhaneh-Sadat
    Shalbafan, Mohammadreza
    Shirazi, Elham
    Akhondzadeh, Shahin
    [J]. PSYCHOPHARMACOLOGY, 2022, 239 (02) : 551 - 559
  • [45] Psychological training to improve psychosocial function in patients with major depressive disorder: A randomised clinical trial
    Knight, Matthew J.
    Lyrtzis, Ellen
    Fourrier, Celia
    Aboustate, Natalie
    Sampson, Emma
    Hori, Hikaru
    Cearns, Micah
    Morgan, Julie
    Toben, Catherine
    Baune, Bernhard T.
    [J]. PSYCHIATRY RESEARCH, 2021, 300
  • [46] Cognitive domains affected by major depressive disorder (MDD)
    Baune, B.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S757 - S757
  • [47] Clinical Predictors of Response to Omega-3 Fatty Acids in Major Depressive Disorder
    Mischoulon, David
    Nierenberg, Andrew A.
    Schettler, Pamela J.
    Kinkead, Becky
    Fehling, Kiki
    Martinson, Max
    Rapaport, Mark Hyman
    [J]. BIOLOGICAL PSYCHIATRY, 2015, 77 (09)
  • [48] Neuroimaging Predictors of Clinical Response and Potential Markers of Treatment with Duloxetine in Major Depressive Disorder
    Fu, Cynthia
    Costafreda, Sergi
    Rasenick, Mark M.
    Donati, Robert
    Liu, Peng
    Marangell, Lauren
    [J]. NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S344 - S344
  • [49] Implications of a Biosignature Study of the Placebo Response in Major Depressive Disorder
    Fava, Maurizio
    [J]. JAMA Psychiatry, 2015, 72 (11) : 1073 - 1074
  • [50] Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial
    Poirot, Maarten G.
    Ruhe, Henricus G.
    Mutsaerts, Henk-Jan M. M.
    Maximov, Ivan I.
    Groote, Inge R.
    Bjornerud, Atle
    Marquering, Henk A.
    Reneman, Liesbeth
    Caan, Matthan W. A.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2024, 181 (03): : 223 - 233
12345